Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity.
about
Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract SurgeryPractical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder SyndromeOnabotulinumtoxinA for the treatment of overactive bladderCUA guideline on adult overactive bladderUrinary retention in female OAB after intravesical Botox injection: who is really at risk?Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder SyndromeEfficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired ContractilityUrodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder.Overactive bladder in elderly men: epidemiology, evaluation, clinical effects, and management.Intradetrusor onabotulinumtoxinA for overactive bladder.Current and potential urological applications of botulinum toxin A.OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.Frailty and Lower Urinary Tract Symptoms.Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study.Individualizing medical treatment of overactive bladder
P2860
Q26749608-1667DA3D-18A7-4D37-B582-919BB6B874DAQ26770415-1F0756E9-677D-4EB4-8C00-021F14FF2FFEQ27002371-A05C0C58-30AC-4414-8899-96A281B3859FQ33665026-FF412236-9AC2-41DE-BF56-4E9D02FA736DQ33705306-CB0910A4-91A0-475A-90D5-D8B80AA6E75FQ34078888-025001F6-53BB-4F5A-B909-274EB7DD2290Q35737565-BC9020EC-BB5F-4480-9215-37FD425E6D2FQ36735604-62314E1C-2717-4371-9F88-7B21FB9218EBQ37682186-23D10B19-974D-49F0-91E9-361D2A03FB22Q38126429-2B3B2D12-A5E5-49A5-A3E7-66F5B65C85B5Q38198733-A494D42B-F15F-4134-BB3F-F31917804E3BQ38564108-28F468EE-9D53-42C2-8453-A92521A7456AQ38669033-5946A81C-AADD-4E6B-98E5-64E8312231C4Q39441063-2097AB5F-DDBE-4515-B60A-65D46300FAE0Q40975843-1DE94C1B-CF37-4C1D-A6CC-45327F40F01CQ41284362-5320DE66-8BC3-4845-B76F-24910431B05BQ57298524-5A10BD7F-A7EF-4787-A961-46ECD061B384
P2860
Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Increased risk of large post-v ...... opathic detrusor overactivity.
@en
Increased risk of large post-v ...... opathic detrusor overactivity.
@nl
type
label
Increased risk of large post-v ...... opathic detrusor overactivity.
@en
Increased risk of large post-v ...... opathic detrusor overactivity.
@nl
prefLabel
Increased risk of large post-v ...... opathic detrusor overactivity.
@en
Increased risk of large post-v ...... opathic detrusor overactivity.
@nl
P1476
Increased risk of large post-v ...... opathic detrusor overactivity.
@en
P2093
Hann-Chorng Kuo
P304
P356
10.1016/J.JURO.2012.11.089
P407
P577
2012-11-20T00:00:00Z